Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
about
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cellsAdoptive cell transfer: a clinical path to effective cancer immunotherapyProducer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsTrial Watch: Adoptive cell transfer for oncological indicationsGenetically modified T cells for the treatment of malignant diseaseImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationStrategies to genetically engineer T cells for cancer immunotherapy.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsRedirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Immunotherapy of human cancers using gene modified T lymphocytes.Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.Spontaneous regression of neoplasms: new possibilities for immunotherapy.Classification of current anticancer immunotherapiesAdoptive-cell-transfer therapy for the treatment of patients with cancerPersonalized cell transfer immunotherapy for B-cell malignancies and solid cancersCombining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.Trial Watch: Adoptive cell transfer immunotherapy.Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.Bcl-2 overexpression enhances tumor-specific T-cell survivalSupernatural T cells: genetic modification of T cells for cancer therapy.Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Adoptive cell transfer therapyAdoptive T-cell transfer in cancer immunotherapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Enhancing adoptive T cell immunotherapy with microRNA therapeutics.Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependentGenetic modification of T cells for immunotherapy.Adoptive cellular immunotherapy for childhood malignancies.Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityNovel therapeutics for the treatment of metastatic melanoma.Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".Enhancing adoptive immunotherapy of cancer.Genetic redirection of T cells for cancer therapy.Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.Designing T cells for cancer immunotherapyHarnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
P2860
Q24621753-86994DCD-4EFE-4D70-AD5B-45895A525395Q24644774-FF5AD70E-1A9E-49A2-A52D-BF43322C019AQ26741260-5463BAAE-C880-4190-A4AD-2EDBBD8E0238Q26785545-2B21F2EC-AFB9-4839-86F1-461648CEE1AAQ26860657-46E74AE7-06F5-4125-857C-36246B8CA996Q28068378-EC51EE71-0DC0-4769-B309-106BFC25A62BQ33655849-1DB32063-7B60-43EF-B26B-6E8D655516C1Q33831940-6CBFA677-A8D6-4F67-85C2-CC81813975C2Q34122292-84776605-00B1-4594-952C-01EF5F630006Q34188383-2D867895-13F6-4ECE-9EF8-DD202CD040CAQ34669675-CF8BA4A3-DBEF-4FFA-8B73-20AD3A79386CQ34701352-27D0E04D-DD59-4754-9A02-C26B85D6881DQ35149637-DA33B7F3-7E2E-4EBB-9320-7D98ACBA16DBQ35210008-7459E1EC-2F22-4EB7-B4BD-F880F3A079EBQ35568556-AE558289-15B3-40EF-8C17-9018EE546BDFQ35623465-4A749BA5-1950-4332-990E-841ED7DE1C26Q35839860-E730D628-983E-409B-A251-82568E10FD5EQ35849500-AFA00350-C89A-4DB8-A410-71CA89A1D1DFQ36057432-E8A261D8-8EEE-4B2B-9142-05867320D150Q36059585-D825F714-D00D-498A-A215-06E88E7161B8Q36327125-D16E46FF-EABC-40B1-A1B0-AE18BB49A561Q36328805-8110808F-48D3-4E3F-B1B1-6071F8C7090AQ36366557-6565174D-CAA3-4381-84DC-A18891DD679CQ36380249-415D09D6-C7EB-44F5-8BE6-A6D913599F23Q36471818-2511B773-702A-46CB-A649-ECB8DB4E3217Q36887833-DE95BFAC-C543-48C9-96BD-3BB824F92AC1Q36889204-C1226A0D-98AD-4157-9BB6-2447BFDBA8F5Q36908573-6DF039B2-E3FF-4EF1-942D-3BE1DB1F2471Q36909362-56E70EA1-CE6B-402E-8E39-3FD614313706Q37008216-2FE8CECE-BFF6-48F8-B3CA-8442F951E898Q37129943-EAEEABDE-46FF-45F4-BE79-55621D1FC3C7Q37469199-33585A95-A1BD-4D65-814D-B209C62281AFQ37486788-66208998-FA2E-4F1C-A67F-E02D12A3FC00Q37570109-60CCB670-27C3-4305-9BF6-B908F6472518Q37585288-0876C681-4849-434C-A5FE-072BBEE32F00Q37687429-16E06A09-F18A-4639-AA57-A59F97ABBDFEQ37697337-FA423DF8-AE6B-4536-9734-E6A6CC886445Q37725751-DAAE5F3C-C8E1-45B7-8ED6-39867A6E6C3FQ37737817-3D6C49EA-9C7E-476D-B386-CCB4087DF7A5Q37809463-94A9E02E-1490-471F-A6AA-FFB8BAD4DC59
P2860
Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Transduction of an IL-2 gene i ...... of specific antitumor activity
@ast
Transduction of an IL-2 gene i ...... of specific antitumor activity
@en
type
label
Transduction of an IL-2 gene i ...... of specific antitumor activity
@ast
Transduction of an IL-2 gene i ...... of specific antitumor activity
@en
prefLabel
Transduction of an IL-2 gene i ...... of specific antitumor activity
@ast
Transduction of an IL-2 gene i ...... of specific antitumor activity
@en
P2860
P1476
Transduction of an IL-2 gene i ...... of specific antitumor activity
@en
P2093
P2860
P304
P356
10.4049/JIMMUNOL.167.11.6356
P407
P577
2001-12-01T00:00:00Z